Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts

NCT03394755 is registered in ClinicalTrials.gov with Cellphire Therapeutics, Inc. as lead sponsor.

NCT NCT03394755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts
Lead sponsor
Cellphire Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2018
Completion date
September 25, 2019
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow aplasia, hematologic diseases, thrombocytopenia